2022
Evaluation of the role of KPNA2 mutations in breast cancer prognosis using bioinformatics datasets
Alnoumas L, van den Driest L, Apczynski Z, Lannigan A, Johnson CH, Rattray NJW, Rattray Z. Evaluation of the role of KPNA2 mutations in breast cancer prognosis using bioinformatics datasets. BMC Cancer 2022, 22: 874. PMID: 35948941, PMCID: PMC9364282, DOI: 10.1186/s12885-022-09969-4.Peer-Reviewed Original ResearchMeSH KeywordsAlpha KaryopherinsBiomarkers, TumorComputational BiologyFemaleHumansMutationNeoplasmsPrognosisConceptsBreast cancer prognosisBreast cancerCancer prognosisFemale cancer-related mortalityPoor patient survival outcomePrecision medicine-based approachKPNA2 overexpressionNovel chemotherapy agentsCancer-related mortalityPatient survival outcomesPoor patient prognosisAggressive tumor phenotypePatient agePrognostic rolePatient survivalSurvival outcomesPatient prognosisLeading causeChemotherapy agentsClinical dataCancer casesClinicopathologic parametersPatient stratificationActionable targetsChemotherapy resistance
2016
Metabolite and Microbiome Interplay in Cancer Immunotherapy
Johnson CH, Spilker ME, Goetz L, Peterson SN, Siuzdak G. Metabolite and Microbiome Interplay in Cancer Immunotherapy. Cancer Research 2016, 76: 6146-6152. PMID: 27729325, PMCID: PMC5093024, DOI: 10.1158/0008-5472.can-16-0309.Peer-Reviewed Original ResearchConceptsMicrobial interactionsRole of metabolitesCancer metabolismColon cancerHost microbiomeBiological originCancer progressionAdenoma/carcinomaPolysaccharide matrixTherapeutic designMetabolomic analysisPotential modulatorsMechanism of actionMicrobiomePolyamine metabolitesCancer immunotherapyBacteriaProximal colonBiofilmsProtective biofilmRecent studiesCancer treatmentMetabolismFuture targetsMetabolites